Li et al. (26) showed that, in advanced stages of heart failure, where increased glycolysis adversely affects mitochondrial uncoupling, oxidative phosphorylation, and cardiac energy supply, the binding of empagliflozin to GLUT1 and GLUT4 may help slow down the progression of the disease. Here, SLC2A1 is linked to heart failure.